Arrowhead Research Corp. (NASDAQ:ARWR) had its price target lowered by research analysts at Jefferies Group from $6.50 to $5.00 in a report released on Thursday. The brokerage currently has a “hold” rating on the stock. Jefferies Group’s price objective suggests a potential upside of 19.62% from the company’s current price.

ARWR has been the topic of several other reports. Chardan Capital set a $10.00 price objective on shares of Arrowhead Research Corp. and gave the company a “buy” rating in a research report on Thursday, September 29th. Cantor Fitzgerald reissued a “buy” rating and issued a $15.00 price objective on shares of Arrowhead Research Corp. in a research report on Thursday, September 29th. Piper Jaffray Cos. dropped their price objective on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 10th. Finally, William Blair assumed coverage on shares of Arrowhead Research Corp. in a research report on Friday, August 19th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $9.81.

Analyst Recommendations for Arrowhead Research Corp. (NASDAQ:ARWR)

Arrowhead Research Corp. (NASDAQ:ARWR) opened at 4.18 on Thursday. Arrowhead Research Corp. has a 52-week low of $3.07 and a 52-week high of $8.22. The firm’s market capitalization is $253.94 million. The firm has a 50-day moving average of $6.44 and a 200-day moving average of $6.18.

In related news, CFO Kenneth Allen Myszkowski sold 6,900 shares of the firm’s stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $8.00, for a total transaction of $55,200.00. Following the transaction, the chief financial officer now directly owns 128,789 shares of the company’s stock, valued at $1,030,312. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Douglas B. Given sold 12,000 shares of the firm’s stock in a transaction dated Friday, October 14th. The stock was sold at an average price of $6.72, for a total transaction of $80,640.00. The disclosure for this sale can be found here. Corporate insiders own 3.90% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Moors & Cabot Inc. raised its position in Arrowhead Research Corp. by 0.6% in the second quarter. Moors & Cabot Inc. now owns 36,270 shares of the company’s stock worth $190,000 after buying an additional 200 shares in the last quarter. ProShare Advisors LLC raised its position in Arrowhead Research Corp. by 1.2% in the second quarter. ProShare Advisors LLC now owns 52,038 shares of the company’s stock worth $277,000 after buying an additional 616 shares in the last quarter. California State Teachers Retirement System raised its position in Arrowhead Research Corp. by 0.7% in the second quarter. California State Teachers Retirement System now owns 126,906 shares of the company’s stock worth $675,000 after buying an additional 852 shares in the last quarter. BlackRock Group LTD raised its position in Arrowhead Research Corp. by 4.7% in the third quarter. BlackRock Group LTD now owns 20,563 shares of the company’s stock worth $152,000 after buying an additional 929 shares in the last quarter. Finally, BlackRock Advisors LLC raised its position in Arrowhead Research Corp. by 4.6% in the second quarter. BlackRock Advisors LLC now owns 27,943 shares of the company’s stock worth $149,000 after buying an additional 1,232 shares in the last quarter. 29.95% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Research Corp. Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

5 Day Chart for NASDAQ:ARWR

Receive News & Stock Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related stocks with our FREE daily email newsletter.